Citigroup Inc. Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Citigroup Inc. acquired a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPRFree Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 61,591 shares of the biotechnology company’s stock, valued at approximately $211,000. Citigroup Inc. owned 0.20% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. GSA Capital Partners LLP increased its position in Capricor Therapeutics by 144.9% during the third quarter. GSA Capital Partners LLP now owns 43,805 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 25,915 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Capricor Therapeutics by 39.5% during the second quarter. Tower Research Capital LLC TRC now owns 12,236 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 3,466 shares during the period. Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 52.1% in the second quarter. Renaissance Technologies LLC now owns 46,421 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 15,900 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Capricor Therapeutics by 4.3% in the second quarter. BlackRock Inc. now owns 410,921 shares of the biotechnology company’s stock valued at $1,964,000 after buying an additional 16,941 shares during the period. Finally, Geode Capital Management LLC grew its position in Capricor Therapeutics by 28.8% during the second quarter. Geode Capital Management LLC now owns 298,322 shares of the biotechnology company’s stock worth $1,426,000 after buying an additional 66,633 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CAPR. StockNews.com raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 24th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Friday, March 1st. Finally, Cantor Fitzgerald began coverage on Capricor Therapeutics in a research note on Friday, January 5th. They issued an “overweight” rating and a $8.00 price objective on the stock.

View Our Latest Research Report on Capricor Therapeutics

Capricor Therapeutics Stock Up 0.3 %

Shares of CAPR stock opened at $6.79 on Friday. Capricor Therapeutics Inc has a twelve month low of $2.68 and a twelve month high of $8.22. The stock’s fifty day simple moving average is $4.80 and its 200 day simple moving average is $4.22. The firm has a market capitalization of $213.89 million, a P/E ratio of -7.80 and a beta of 3.94.

Capricor Therapeutics (NASDAQ:CAPRGet Free Report) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.21. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. The business had revenue of $12.09 million during the quarter, compared to analyst estimates of $5.80 million. As a group, equities research analysts expect that Capricor Therapeutics Inc will post -0.83 EPS for the current fiscal year.

Capricor Therapeutics Profile

(Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also

Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics Inc (NASDAQ:CAPRFree Report).

Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.